Home
Healthcare
Healthcare & Pharmaceuticals
Multiple Myeloma Market Size, Industry Trends Report | 2031

Multiple Myeloma Market

Name: Growth Market Reports
Address: 500 East E Street, Ontario, 91764, USA
Telephone: +1 909 414 1393

Segments - by Types (Active Multiple Myeloma and Smoldering Multiple Myeloma), Diagnosis (Urine Test, Blood Test, Bone Marrow Test, Imaging Test, specialized Test, and Others), Treatments (Radiation Therapy, Medication, Stem Cell Transplant, and Others), Dosage Forms (Tablets, Injections, Capsules, and Others), Routes of Administration (Parenteral, Oral, and Others), Distribution Channels (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, and Others), End-users (Specialty Clinics, Homecare, Hospitals, and Others), and Regions (Asia Pacific, North America, Latin America, Europe and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2022 – 2030

HC-4206
4.7 Rating
180 Pages

Upcoming
84 Reviews

Author :

Raksha Sharma

Fact-checked by :

Vineet Pandey

Editor :

Vishal Golekar

Report Description

The global multiple myeloma market size was valued at around USD 19.5 billion in 2021 and is estimated to reach USD 30.1 billion by 2030, expanding at a CAGR of around 4.1% during the forecast period, 2022 – 2030. The growth of the market is attributed to the higher amount of diagnosis of the disease and increasing sophistication of treatments.

Multiple myeloma is a type of cancer that forms in white blood cells called plasma cells. Healthy plasma cells make antibodies, which recognize and attack germs and fight infections. In multiple myeloma, cancerous plasma cells amass in the bone marrow, which force out healthy blood cells. These cancerous cells produce unusual proteins that cause health complications. Symptoms of multiple myeloma do not occur in early stages of the disease. Signs and symptoms usually occur in later stages of disease such as bone pain, nausea, loss of appetite, fatigue, constipation, weight loss, excessive thirst, weakness in legs, and others. Although researchers are not sure regarding the exact causes of multiple myeloma, some protentional causes include genetic mutation, inflammatory diseases, obesity, and exposure to radiation and chemicals. Multiple myeloma is considered treatable; however, it is considered as incurable. Healthcare providers provide some treatments to control and manage the symptoms, such as pain medications, steroids, antibiotics, stem cell transplants, and radiation therapies.

Market Trends, Drivers, Restraints, and Opportunities

Increasing prevalence of multiple myeloma is expected to drive the market during the forecast period.
Growing investments in technological advancements in the medical field boosts the market.
Surging number of drug launches and approvals is estimated to fuel the market in the coming years.
Rising cost of treatments is anticipated to hamper the growth of the market during the forecast period.
Increasing number of research & development activities regarding multiple myeloma offers growth opportunities to the key market players.

Scope of the Report

The report on the global multiple myeloma market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Multiple Myeloma Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2021
Historic Data	2019–2020
Forecast Period	2022–2030
Segmentation	Types (Active Multiple Myeloma and Smoldering Multiple Myeloma), Diagnosis (Urine Test, Blood Test, Bone Marrow Test, Imaging Test, Specialized Test, and Others), Treatments (Radiation Therapy, Medication, Stem Cell Transplant, and Others), Dosage Forms (Tablets, Injections, Capsules, and Others), Routes of Administration (Parenteral, Oral, and Others), Distribution Channels (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, and Others), and End-users (Specialty Clinics, Homecare, Hospitals, and Others)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	AbbVie, Inc.; Gland Pharma Limited; F. Hoffmann-La Roche Ltd; Sanofi; Johnson & Johnson Services, Inc.; Pfizer, Inc.; Novartis International AG; Eagle Pharmaceuticals, Inc.; GSK Group of Companies; Teva Pharmaceuticals Industries, Ltd.; Fresenius Kabi AG; Bristol-Myers Squibb Company; Alvogen; Hikma Pharmaceuticals PLC; Bayer AG; Cipla, Inc.; Lupin Limites; Sun Pharmaceuticals Industries, Ltd.; and Others

Market Segment Insights

Smoldering multiple myeloma segment drives the market

Based on Types, the global multiple myeloma market is divided into Active Multiple Myeloma and Smoldering Multiple Myeloma. The smoldering multiple myeloma market is expected to boost the market during the forecast period, as it is an asymptomatic disease with no cure for it available. The active multiple myeloma market is anticipated to expand during in the coming years, as there are treatments to cure the cancer.

Specialized test segment boosts the market

In terms of diagnosis, the market is segmented into urine test, blood test, bone marrow test, imaging test, specialized test, and others. The specialized test segment is projected to drive the market during the forecast period, as specialized tests such as fluorescence in situ hybridization (FISH) analyze multiple myeloma cells to identify gene mutations for precise results. The blood test and bone marrow test segments are estimated to spur the market in the coming years, as these tests are easily available and commonly used to diagnose multiple myeloma.

Radiation therapy segment dominates the market

Based on treatments, the market is divided into radiation therapy, medication, stem cell transplant, and others. The radiation therapy segment is estimated to expand at a rapid pace, as it effectively treats multiple myeloma in specific situation and lower complications from bone disease.

Tablets segment holds a key market share

On the basis of dosage forms, the market is segregated into tablets, injections, capsules, and others. The tablets segment is estimated to fuel the market during the forecast period, as tablets are easily available and easy to consume. The capsules segment is anticipated to expand during the forecast period, due to its availability and easy usage.

Oral segment fuels the market

In terms of routes of administration, the market is divided into parenteral, oral, and others. The oral segment is expected to boost the market during the forecast period, as oral drugs prevent further bone damage and they are easy to consume.

Hospital pharmacy segment holds a key market share

Based on distribution channels, the market is segmented into retail pharmacy, hospital pharmacy, online pharmacy, and others. The hospital pharmacy segment is expected to drive the market during the forecast period, as availability of regularly prescribed and administered drugs in hospital settings in hospital pharmacracies. Higher administration of intravenous therapeutics aid in the expansion of the hospital pharmacy segment. The online pharmacy segment is anticipated to expand rapidly during the projected period, due to its ease and convenience in filling up the prescriptions.

Specialty clinics segment boosts the market

On the basis of end-users, the market segregated into specialty clinics, homecare, hospitals, and others. The specialty clinics segment is projected to boost the market during the forecast period, due to availability of doctors specializing in treating blood and bone marrow disorders or doctors specializing in treating cancer in such clinics.

North America dominates the market

In terms of regions, the market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is expected to register a significant CAGR during the forecast years, due to growing prevalence of blood cancer and rising geriatric population in the region. Changing lifestyles and increasing demand for biologic therapies in North America is propels the market in the region. The market in Asia Pacific is anticipated to expand during the forecast period, owing increasing penetration of novel cancer drugs, growing obesity, and rising healthcare expenditure in the region.

Segments

The global multiple myeloma- market has been segmented on the basis of

Types

Active Multiple Myeloma
Smoldering Multiple Myeloma

Diagnosis

Urine Test
Blood Test,
Bone Marrow Test
Imaging Test
Specialized Test
Others

Treatments

Radiation Therapy
Medication
Stem Cell Transplant
Others

Dosage Forms

Tablets
Injections
Capsules
Others

Routes of Administration

Parenteral
Oral
Others

Distribution Channels

Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Others

End-users

Specialty Clinics
Homecare
Hospitals
Others

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

AbbVie, Inc.
Gland Pharma Limited
F. Hoffmann-La Roche Ltd
Sanofi
Johnson & Johnson Services, Inc.
Pfizer, Inc.
Novartis International AG
Eagle Pharmaceuticals, Inc.
GSK Group of Companies
Teva Pharmaceuticals Industries, Ltd.
Fresenius Kabi AG
Bristol-Myers Squibb Company
Alvogen
Hikma Pharmaceuticals PLC
Bayer AG
Cipla, Inc.
Lupin Limited
Sun Pharmaceuticals Industries, Ltd.
Others

Competitive Landscape

The global multiple myeloma market is highly competitive with the presence of key players such as AbbVie, Inc.; Gland Pharma Limited; F. Hoffmann-La Roche Ltd; Sanofi; Johnson & Johnson Services, Inc.; Pfizer, Inc.; Novartis International AG; Eagle Pharmaceuticals, Inc.; GSK Group of Companies; Teva Pharmaceuticals Industries, Ltd.; Fresenius Kabi AG; Bristol-Myers Squibb Company; Alvogen; Hikma Pharmaceuticals PLC; Bayer AG; Cipla, Inc.; Lupin Limited; Sun Pharmaceuticals Industries, Ltd.; and others, who use strategies such as mergers, acquisitions, product launches, collaborations, and partnerships to strengthen their hold on the market. For example, May 2022, Gland Pharma Limited launched Bortezomib for injections to treat multiple myeloma. In April 2022, Sanofi launched Diversity, Equity, & Inclusion Board (DE&I), which is a first-of-a-kind board to feature outside advisors.

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Multiple Myeloma Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Multiple Myeloma Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Multiple Myeloma Market - Supply Chain
  4.5. Global Multiple Myeloma Market Forecast
     4.5.1. Multiple Myeloma Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Multiple Myeloma Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Multiple Myeloma Market Absolute $ Opportunity
5. Global Multiple Myeloma Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Multiple Myeloma Market Size and Volume Forecast by Types
     5.3.1. Active Multiple Myeloma
     5.3.2. Smoldering Multiple Myeloma
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Multiple Myeloma Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Multiple Myeloma Market Size and Volume Forecast by End Users
     6.3.1. Specialty Clinics
     6.3.2. Homecare
     6.3.3. Hospitals
     6.3.4. Others
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Multiple Myeloma Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Multiple Myeloma Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Multiple Myeloma Demand Share Forecast, 2019-2026
8. North America Multiple Myeloma Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Multiple Myeloma Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Multiple Myeloma Market Size and Volume Forecast by Types
     8.4.1. Active Multiple Myeloma
     8.4.2. Smoldering Multiple Myeloma
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Multiple Myeloma Market Size and Volume Forecast by End Users
     8.7.1. Specialty Clinics
     8.7.2. Homecare
     8.7.3. Hospitals
     8.7.4. Others
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Multiple Myeloma Demand Share Forecast, 2019-2026
9. Latin America Multiple Myeloma Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Multiple Myeloma Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Multiple Myeloma Market Size and Volume Forecast by Types
     9.4.1. Active Multiple Myeloma
     9.4.2. Smoldering Multiple Myeloma
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Multiple Myeloma Market Size and Volume Forecast by End Users
     9.7.1. Specialty Clinics
     9.7.2. Homecare
     9.7.3. Hospitals
     9.7.4. Others
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Multiple Myeloma Demand Share Forecast, 2019-2026
10. Europe Multiple Myeloma Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Multiple Myeloma Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Multiple Myeloma Market Size and Volume Forecast by Types
     10.4.1. Active Multiple Myeloma
     10.4.2. Smoldering Multiple Myeloma
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Multiple Myeloma Market Size and Volume Forecast by End Users
     10.7.1. Specialty Clinics
     10.7.2. Homecare
     10.7.3. Hospitals
     10.7.4. Others
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Multiple Myeloma Demand Share Forecast, 2019-2026
11. Asia Pacific Multiple Myeloma Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Multiple Myeloma Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Multiple Myeloma Market Size and Volume Forecast by Types
     11.4.1. Active Multiple Myeloma
     11.4.2. Smoldering Multiple Myeloma
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Multiple Myeloma Market Size and Volume Forecast by End Users
     11.7.1. Specialty Clinics
     11.7.2. Homecare
     11.7.3. Hospitals
     11.7.4. Others
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Multiple Myeloma Demand Share Forecast, 2019-2026
12. Middle East & Africa Multiple Myeloma Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Multiple Myeloma Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Multiple Myeloma Market Size and Volume Forecast by Types
     12.4.1. Active Multiple Myeloma
     12.4.2. Smoldering Multiple Myeloma
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Multiple Myeloma Market Size and Volume Forecast by End Users
     12.7.1. Specialty Clinics
     12.7.2. Homecare
     12.7.3. Hospitals
     12.7.4. Others
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Multiple Myeloma Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Multiple Myeloma Market: Market Share Analysis
  13.2. Multiple Myeloma Distributors and Customers
  13.3. Multiple Myeloma Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. AbbVie, Inc.
     13.4.2. Gland Pharma Limited
     13.4.3. F. Hoffmann-La Roche Ltd
     13.4.4. Sanofi
     13.4.5. Johnson & Johnson Services, Inc.
     13.4.6. Pfizer, Inc.
     13.4.7. Novartis International AG
     13.4.8. Eagle Pharmaceuticals, Inc.
     13.4.9. GSK Group of Companies
     13.4.10. Teva Pharmaceuticals Industries, Ltd.

Methodology

Purchase Premium Report

Buy Now

Request For Sample

Request For Customization

Enquiry Before Buying

Speak With Analyst

Customize This Report

Ask for Research To Be Focused On Specific Regions or Segments
Receive Data As Per Your Format and Definition
Companies Profiled based on Your Requirements
Breaking Down Competitive Landscape as per Your Requirements
Any Level of Customization

Our Clients

Client Testinomials

We needed a highly accurate and precise report, which Growth Market Reports delivered promptly. The company compiled information from a wide array of reliable agencies and sourcess.It is extremely satisfactory to be working with you.
Strategy Head of Major Tech Company

We were very pleased to contact Growth Market Reports as they tailored reports precisely as per our requirements. As we are dealing with the aerospace and defense industry, we need reports of high accuracy and substantial quality.
Major Player in Defense Industry

Extremely delighted to have a well-crafted report on “Global Packaging Solutions Market Research Report” from your team. Thank you for providing me with all our requirements and for incorporating our suggestions.
CMO of Leading Packaging Company from USA

I had a good experience working with Growth Market Reports as they were very open to all constructive changes in the report. I found that the report had its charm embedded with ample of data.
Founder and Managing Partner of Major Korean Company

Our company has been working with Growth Market Reports for some years now and we are very happy with the quality of the reports provided by the company.I, on behalf of my organization, would like to thank you for offering professional reports.
Global Consulting Firm

Quick Contact

+1 909 414 1393

sales@growthmarketreports.com

Growth Market Report

Certified By

FAQ Section

Some frequently asked questions about this report!

1. Who are the key players in the global multiple myeloma market?

AbbVie, Inc.; Gland Pharma Limited; F. Hoffmann-La Roche Ltd; Sanofi; Johnson & Johnson Services, Inc.; Pfizer, Inc.; Novartis International AG; Eagle Pharmaceuticals, Inc.; GSK Group of Companies; and Teva Pharmaceuticals Industries, Ltd. are some of the key players in the market.